tirzepatide v vs. Semaglutide for Weight Loss hormone GLP Retatrutide vs. Tirzepatide: What's The

The Study at a Glance Who was studied: 132 children and adolescents aged 1017 with type 2 diabetes Duration: 52 weeks (with the primary endpoint measured at week 26) Design: Randomized, double-blind, placebo-controlled Drug: Oral semaglutide at once-daily doses of 3 mg, 7 mg, or 14 mg Background therapy: Participants continued on metformin, basal insulin, or both The Results The trial met its primary endpoint

Come tutti i farmaci, la tirzepatide pu causare effetti collaterali che importante conoscere

Both peptides appear to require indefinite use for sustained weight maintenance, similar to how blood pressure medications require ongoing use to maintain effect

doi: 10.3389/fendo.2021.645563 25 HughesSNeumillerJJ